[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].

Gregory P Arutyunov Yuri Lopatin A S Ametov Fail T Ageev M B Antsiferov S V Villevalde N G Vinogradova A M Gorbacheva A S Galyavich S R Gilyarevskiy M G Glezer Igor Zhirov Mikhail Vitalyevich Ilyin A I Lebedeva S M Nedogoda V V Salukhov G P Arutiunov Sergey Tereshchenko I V Fomin I S Khalimov N R Khasanov D V Cherkashin Sergey Yakushin

Published in: Terapevticheskii arkhiv (2021)

At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.

Keyphrases